Clinical Report: Inflammatory Reactions in Biologic Therapy: A Mechanistic Overview
Overview
This report discusses paradoxical inflammatory reactions associated with biologic therapies, particularly in pediatric populations. It highlights the need for a unified mechanistic framework and a practical clinical approach to manage these reactions effectively.
Background
Paradoxical inflammatory reactions during biologic therapy pose significant challenges in treating immune-mediated diseases. These reactions can lead to new inflammatory conditions or exacerbation of existing diseases, complicating patient management. Understanding the underlying mechanisms is crucial for optimizing treatment strategies and improving patient outcomes.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
Paradoxical inflammatory reactions, termed flip–flop phenomena, can occur during biologic therapy.
These reactions may involve new inflammatory phenotypes or worsening of the primary disease despite prior therapeutic success.
Five pediatric cases illustrate distinct pathways leading to various inflammatory responses during biologic treatment.
Dynamic interactions between immune pathways (Th1/Th17, Th2, and interferon–JAK/STAT) contribute to these paradoxical reactions.
A practical diagnostic and therapeutic algorithm is proposed for managing flip–flop reactions in clinical settings.
Clinical Implications
Clinicians should be aware of the potential for paradoxical inflammatory reactions in patients receiving biologic therapies. Early recognition and a severity-adapted management approach may improve treatment outcomes and patient safety.
Conclusion
A unified understanding of paradoxical inflammatory reactions can enhance clinical decision-making in biologic therapy. This report emphasizes the importance of recognizing immune rebalancing as a therapeutic goal.
